Oculis Holding (CR5) Stock Overview
A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CR5 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Oculis Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.00 |
| 52 Week High | US$26.00 |
| 52 Week Low | US$13.05 |
| Beta | 0.21 |
| 1 Month Change | 9.45% |
| 3 Month Change | -8.71% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 173.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| CR5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.2% | -6.3% | -1.8% |
| 1Y | n/a | 11.5% | 2.6% |
Return vs Industry: Insufficient data to determine how CR5 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CR5 performed against the German Market.
Price Volatility
| CR5 volatility | |
|---|---|
| CR5 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: CR5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CR5's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 60 | Riad Sherif | oculis.com |
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.
Oculis Holding AG Fundamentals Summary
| CR5 fundamental statistics | |
|---|---|
| Market cap | €1.37b |
| Earnings (TTM) | -€107.05m |
| Revenue (TTM) | €1.30m |
Is CR5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CR5 income statement (TTM) | |
|---|---|
| Revenue | CHF 1.20m |
| Cost of Revenue | CHF 57.09m |
| Gross Profit | -CHF 55.89m |
| Other Expenses | CHF 43.07m |
| Earnings | -CHF 98.96m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -1.67 |
| Gross Margin | -4,661.05% |
| Net Profit Margin | -8,253.29% |
| Debt/Equity Ratio | 0% |
How did CR5 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/28 14:46 |
| End of Day Share Price | 2026/04/28 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oculis Holding AG is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Daniil Gataulin | Chardan Capital Markets, LLC |